Design Therapeutics Inc DSGN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $4.72
- Day Range
- $4.70–5.02
- 52-Week Range
- $1.96–6.91
- Bid/Ask
- $4.87 / $5.33
- Market Cap
- $283.10 Mil
- Volume/Avg
- 201,277 / 263,304
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company’s product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 57
- Website
- https://www.designtx.com
Comparables
Valuation
Metric
|
DSGN
|
EWTX
|
TNYA
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.08 | 5.21 | 1.04 |
Price/Sales | — | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
DSGN
|
EWTX
|
TNYA
|
---|---|---|---|
Quick Ratio | 41.04 | 29.79 | 5.94 |
Current Ratio | 41.42 | 30.24 | 6.28 |
Interest Coverage | — | — | — |
Quick Ratio
DSGN
EWTX
TNYA
Profitability
Metric
|
DSGN
|
EWTX
|
TNYA
|
---|---|---|---|
Return on Assets (Normalized) | −13.14% | −23.23% | −55.72% |
Return on Equity (Normalized) | −13.70% | −24.43% | −66.08% |
Return on Invested Capital (Normalized) | −13.56% | −29.19% | −64.65% |
Return on Assets
DSGN
EWTX
TNYA
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Novo Nordisk AS ADR
NVO
| Xshzmsglk | Qpm | $512.4 Bil | |||
Vertex Pharmaceuticals Inc
VRTX
| Jdcrjtqxv | Mzclqnv | $117.5 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Ppvpcfrl | Mghyh | $111.6 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Pcchrsdr | Qqnhgh | $34.4 Bil | |||
argenx SE ADR
ARGX
| Ktwzvcztj | Bmlb | $31.7 Bil | |||
BioNTech SE ADR
BNTX
| Gbbcwmrp | Fntyt | $29.2 Bil | |||
Moderna Inc
MRNA
| Mzffdjm | Ghhk | $23.1 Bil | |||
United Therapeutics Corp
UTHR
| Tspwtnk | Yqnz | $15.8 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Ghnwwss | Yqdzz | $13.2 Bil | |||
Incyte Corp
INCY
| Zvmymnlj | Bvywdt | $13.0 Bil |